Key result
Xuezhitong capsule combined with conventional treatment improved total clinical effectiveness to 89.5% compared to 72.9% with conventional treatment alone in patients with microvascular angina.
Why the study?
To evaluate the therapeutic effect of Xuezhitong capsule and its impact on vascular endothelial function in patients with microvascular angina.
Does Xuezhitong capsule added to conventional treatment improve clinical efficacy and endothelial function in patients with microvascular angina?
RCT (n=171)
Random number table method
No
Does Xuezhitong capsule added to conventional treatment improve clinical efficacy and endothelial function in patients with microvascular angina?
Absolute Event Rate: 89.53% vs 72.94%
p-value: p=0.005
The addition of Xuezhitong capsule to conventional therapy significantly improved angina symptoms, endothelial function, and lipid profiles while reducing inflammation and adverse events in patients with microvascular angina.
Supports adjunctive Xuezhitong in microvascular angina; extends RCT evidence for herbal therapies targeting endothelial function.
Purpose: To determine the therapeutic effect of Xuezhitong capsule in patients with microvascular angina (MVA), and its impact on vascular endothelial function.Methods: In total, 172 MVA patients treated in Beijing City Fengtai District Nanyuan Hospital from September 2017 to September 2019 were selected and randomized into control group which received conventional treatment, and treatment group which received Xuezhitong capsules plus. There were 86 patients in each group. Therapeutic effect, levels of inflammatory factors, i.e., high-sensitivity C- reactive protein (hs-CRP), interleukin-(IL-6), tumor necrosis factor-α (TNF-α), and vascular endothelial factors such as nitric oxide (NO), thromboxane B2 (TXB2) and endothelin (ET), were determined.Results: Markedly higher total treatment effectiveness was observed in the treatment group than in the control group (89.53 % vs. 72.94 %; p < 0.05). In both groups, treatment reduced the levels of hs-CRP, IL-6, TNF-α, TXB2 and ET, but elevated NO, with better results for treatment group than the control group (p < 0.05). Better optimizations of total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein (HDL) were observed in the treatment group, relative to the control group (p < 0.05). Patients in the treatment group experienced fewer (8.14%) adverse reactions than those in control group (21.18 %, p < 0.05).Conclusion: Xuezhitong capsule, when combined with conventional treatment, exerts high therapeutic effectiveness and safety in MVA patients by inhibiting inflammatory reactions, optimizing endothelialfunction, reducing blood lipid levels, and decreasing the incidence of cardiovascular adverse events. Thus, the combination therapy is a potentially superior therapeutic strategy to the conventional approach for the management of MVA patients.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2021) conducted an RCT in Microvascular angina (n=171). Xuezhitong capsule vs. Conventional treatment was evaluated on Total treatment effectiveness (reduction in angina episodes) (p=0.005). Xuezhitong capsule combined with conventional treatment improved total clinical effectiveness to 89.5% compared to 72.9% with conventional treatment alone in patients with microvascular angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: